Browse Category

NASDAQ:PLRZ News 2 December 2025 - 4 December 2025

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday swings between roughly $12.5 and $18.2 and volume near 26 million shares – over 20× its recent average. MarketBeat+1 Behind this violent move are two concrete catalysts: At the same time, quantitative services and technical models are sending mixed—and often cautious—signals, with several “Strong Sell” ratings even as momentum screens flash “Buy” or “Strong Buy.” TipRanks+4Danelfin AI+4TradingView+4 This article walks
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. (NASDAQ: PLRZ) has exploded into the spotlight after a two‑day run that has turned an obscure micro‑cap biotech into one of the most talked‑about healthcare stocks on the Nasdaq. By early afternoon on December 4, 2025, Polyrizon shares were trading around $13–15, nearly doubling from Wednesday’s close at $7.09, with intraday highs reported above $18 and gains briefly exceeding 100–130%, according to MarketBeat, Investing.com and other real‑time data providers. 24/7 MarketNews+3MarketBeat+3StockAnalysis+3 At the heart of this move are two catalysts: Together, these updates have ignited speculative interest in a company that, until recently, was fighting to stay listed
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (NASDAQ: PLRZ) has suddenly jumped from obscure micro‑cap to headline mover. On Tuesday, December 2, 2025, the Israeli biotech’s shares spiked roughly 130% in a single session after the company announced a key manufacturing upscaling milestone for its PL‑14 nasal allergy blocker platform. The stock closed at about $7.33 on Tuesday—up from $3.16 the prior session—with intraday highs above $8 and trading volume near 150 million shares. Pre‑market quotes on December 3 show the stock around $6, still dramatically higher than earlier in the week. StockAnalysis+1 The move comes from a tiny base. Polyrizon is a development‑stage biotech
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

On December 2, 2025, Polyrizon Ltd. (NASDAQ: PLRZ) went from obscure micro-cap to center stage as its stock exploded more than 130% in a single session after the company announced a key manufacturing milestone for its flagship nasal spray platform.MarketScreener+1 The move capped one of the wildest trading days the stock has seen since its 2024 IPO: shares closed around $7.33, up 131.96% on the day, with intraday prices swinging between $5.85 and $8.36 and volume surging past 148 million shares.StockAnalysis Other outlets tracking real‑time tape during the session quoted gains ranging from roughly 80% to 142%, depending on the

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop